Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022.

The prerecorded presentation will become available on Tuesday, May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When is Protara's presentation at the H.C. Wainwright Global Investment Conference?

Protara's presentation will be available on May 24, 2022, at 7:00 a.m. ET.

What is TARA-002?

TARA-002 is an investigational cell-based therapy developed by Protara for treating non-muscle invasive bladder cancer and lymphatic malformations.

How can I access Protara's conference presentation?

The presentation can be accessed on Protara's website in the Events and Presentations section.

What is the focus of Protara Therapeutics?

Protara focuses on developing transformative therapies for cancer and rare diseases with limited treatment options.

Where can I find more information about Protara Therapeutics?

More information can be found on Protara's official website at www.protaratx.com.